1 of 1
Story summary
- Strive Specialties filed a Texas lawsuit against Eli Lilly and Novo Nordisk, alleging exclusive telehealth partnerships block access to customized GLP-1 weight-loss drugs and limit compounded prescriptions.
- The lawsuit seeks monetary damages and a court order to halt the exclusivity agreements.
- Eli Lilly and Novo Nordisk deny the allegations and say they will defend the claims.
- Following the news, shares fell: Eli Lilly by 3.67% and Novo Nordisk by 3.40%.
